Rheonix Plans FDA Submission for Warfarin Sensitivity Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rheonix today said that it intends to file for US Food and Drug Administration clearance for its warfarin sensitivity test on its CARD platform.

The Ithaca, NY-based startup said that it intends to file a 510(k) application for the test, which detects three SNPs — VKOR1, CYP2C9*2, and CYP2C9*3 — associated with warfarin sensitivity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.